127 related articles for article (PubMed ID: 2458582)
1. Relationship of prostatic acid phosphatase localization in human prostate by a monoclonal antibody with the Gleason grading system.
Sinha AA; Gleason DF; Wilson MJ; Wick MR; Reddy PK; Blackard CE
Prostate; 1988; 13(1):1-15. PubMed ID: 2458582
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of PAP and PSA gene expression in prostatic hyperplasia and prostatic carcinoma using northern-blot analyses, in situ hybridization and immunohistochemical stainings with monoclonal and bispecific antibodies.
Hakalahti L; Vihko P; Henttu P; Autio-Harmainen H; Soini Y; Vihko R
Int J Cancer; 1993 Oct; 55(4):590-7. PubMed ID: 7691762
[TBL] [Abstract][Full Text] [Related]
3. Immunohistochemical staining for DNA topoisomerase II-alpha in benign, premalignant, and malignant lesions of the prostate.
Willman JH; Holden JA
Prostate; 2000 Mar; 42(4):280-6. PubMed ID: 10679757
[TBL] [Abstract][Full Text] [Related]
4. Immunohistochemical distribution of the three predominant secretory proteins in the parenchyma of hyperplastic and neoplastic prostate glands.
Abrahamsson PA; Lilja H; Falkmer S; Wadström LB
Prostate; 1988; 12(1):39-46. PubMed ID: 2450341
[TBL] [Abstract][Full Text] [Related]
5. Enzyme immunoassay of prostatic acid phosphatase after prostatic examination. Correlation with prostate size and immunopathology.
el-Shirbiny AM; Shridhar P; al Adnani MS; Suresh LK
Urology; 1988 Nov; 32(5):469-73. PubMed ID: 2460989
[TBL] [Abstract][Full Text] [Related]
6. Creatine phosphokinase isoenzymes in human prostatic tissues: a comparison between benign hyperplasia and adenocarcinoma.
Truong T; Carmel M; Elhilali M; Cloutier D; Lehoux JG
Prostate; 1985; 7(2):143-9. PubMed ID: 2413430
[TBL] [Abstract][Full Text] [Related]
7. Alpha-methylacyl-CoA racemase (P504S) expression in evolving carcinomas within benign prostatic hyperplasia and in cancers of the transition zone.
Leav I; McNeal JE; Ho SM; Jiang Z
Hum Pathol; 2003 Mar; 34(3):228-33. PubMed ID: 12673556
[TBL] [Abstract][Full Text] [Related]
8. Immunocytochemical demonstration of prostatic acid phosphatase: different secretion kinetics between normal, hyperplastic and neoplastic prostates.
Mori K; Wakasugi C
J Urol; 1985 May; 133(5):877-83. PubMed ID: 2580998
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of commercial immunoperoxidase kits for prostatic specific antigen and prostatic specific acid phosphatase.
Svanholm H
Acta Pathol Microbiol Immunol Scand A; 1986 Jan; 94(1):7-12. PubMed ID: 2421532
[TBL] [Abstract][Full Text] [Related]
10. Ratio of cathepsin B to stefin A identifies heterogeneity within Gleason histologic scores for human prostate cancer.
Sinha AA; Quast BJ; Wilson MJ; Fernandes ET; Reddy PK; Ewing SL; Sloane BF; Gleason DF
Prostate; 2001 Sep; 48(4):274-84. PubMed ID: 11536307
[TBL] [Abstract][Full Text] [Related]
11. Immunohistochemical prostatic acid phosphatase level as a prognostic factor of prostatic carcinoma.
Sakai H; Shiraishi K; Minami Y; Yushita Y; Kanetake H; Saito Y
Prostate; 1991; 19(3):265-72. PubMed ID: 1946042
[TBL] [Abstract][Full Text] [Related]
12. Immunochemical studies of prostatic acid phosphatase.
Choe BK; Pontes EJ; McDonald I; Rose NR
Cancer Treat Rep; 1977; 61(2):201-4. PubMed ID: 68823
[TBL] [Abstract][Full Text] [Related]
13. Immunohistochemical identification of prostatic acid phosphatase: correlation of tumor grade with acid phosphatase distribution.
Bates RJ; Chapman CM; Prout GR; Lin CW
J Urol; 1982 Mar; 127(3):574-80. PubMed ID: 6174741
[TBL] [Abstract][Full Text] [Related]
14. The histochemical behaviour, electrophoretic mobility and distribution in cell fractions of acid phosphatase isozymes in prostatic cancer and benign prostate hyperplasia.
Fischer DR; Gevers W; Klerk JN; Kühn S
Int Urol Nephrol; 1979; 11(2):111-8. PubMed ID: 89105
[TBL] [Abstract][Full Text] [Related]
15. Acid phosphatase localization in prostatic carcinoma. A comparison of monoclonal antibody to heteroantisera.
Shevchuk MM; Romas NA; Ng PY; Tannenbaum M; Olsson CA
Cancer; 1983 Nov; 52(9):1642-6. PubMed ID: 6193862
[TBL] [Abstract][Full Text] [Related]
16. The significance of prostatic acid phosphatase in adenocarcinoma of the prostate.
Bruce AW; Mahan DE; Sullivan LD; Goldenberg L
J Urol; 1981 Mar; 125(3):357-60. PubMed ID: 6162968
[TBL] [Abstract][Full Text] [Related]
17. Immunohistochemical localization of prostate-specific acid phosphatase and prostate-specific antigen in stage A2 adenocarcinoma of the prostate: prognostic implications.
Epstein JI; Eggleston JC
Hum Pathol; 1984 Sep; 15(9):853-9. PubMed ID: 6381284
[TBL] [Abstract][Full Text] [Related]
18. Distribution of prostatic acid phosphatase isoenzymes in normal and cancerous states.
Lad PM; Learn DB; Cooper JF; Reisinger DM
Clin Chim Acta; 1984 Aug; 141(1):51-65. PubMed ID: 6467620
[TBL] [Abstract][Full Text] [Related]
19. Changes in immunohistochemical staining of PSA, PAP, and TURP-27 following irradiation therapy for clinically localized prostate cancer.
Grob BM; Schellhammer PF; Brassil DN; Wright GL
Urology; 1994 Oct; 44(4):525-9. PubMed ID: 7524238
[TBL] [Abstract][Full Text] [Related]
20. Serial lectin affinity chromatography with concavalin A and wheat germ agglutinin demonstrates altered asparagine-linked sugar-chain structures of prostatic acid phosphatase in human prostate carcinoma.
Yoshida KI; Honda M; Arai K; Hosoya Y; Moriguchi H; Sumi S; Ueda Y; Kitahara S
J Chromatogr B Biomed Sci Appl; 1997 Aug; 695(2):439-43. PubMed ID: 9300882
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
